NCT06012331

Brief Summary

The aim of this study is to compare clinical and radiographic evaluation treatment of necrotic immature permanent teeth using:

  1. 1.Concentrated Growth Factor
  2. 2.Blood Clot

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 7, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

August 25, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

February 6, 2024

Status Verified

September 1, 2023

Enrollment Period

6 months

First QC Date

August 7, 2023

Last Update Submit

February 5, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • clinically successful treatment

    The treatment will be considered to be clinically successful when. Absence of pain will record it by verbal question to patient/ parent. Absence of tenderness to percussion) will record it by percussion test (by the back of the dental mirror) Absence of swelling and fistula or sinus tract -- will record it by visual clinical examination

    3,6,9,12 months

Secondary Outcomes (1)

  • Radiographic Success treatment

    6, 12 months

Study Arms (2)

Concentrated Growth Factor (CGF)

EXPERIMENTAL

Concentrated growth factor (CGF) is relatively a new generation of platelet concentrate product, it contains more cytokines and growth factors compared with PRP and PRF also promotes the proliferation, migration, and differentiation of stem cells

Procedure: concentrated growth factors in open apexProcedure: Blood Clot (BC)

Blood Clot (BC)

ACTIVE COMPARATOR

Inducing bleeding to facilitate healing is a common surgical procedure. The blood clot formed after hemorrhage, acts as a scaffold and rich source of growth factors, and could play an important role in tissue repair in the canal. The growth factors could stimulate differentiation, growth, and maturation of fibroblasts, odontoblasts and cementoblasts, from the immature undifferentiated mesenchymal cells in the newly formed tissue matrix

Procedure: concentrated growth factors in open apexProcedure: Blood Clot (BC)

Interventions

Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors. CGF will be packed into canal to the full working length using sterile pluggers. The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration

Blood Clot (BC)Concentrated Growth Factor (CGF)

1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level) 2. Stop bleeding at a level that allows for 3-4 mm of restorative material. 3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration.

Blood Clot (BC)Concentrated Growth Factor (CGF)

Eligibility Criteria

Age8 Years - 14 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children aged between 8\_14 years.
  • Anterior tooth diagnosed with necrotic pulp (due to trauma, caries, or anomaly) responded negatively to sensibility tests.
  • Teeth not indicated for post and core.
  • A cooperative and compliant patient/parent.
  • Patients not allergic to medicaments necessary to complete the procedure.
  • Patients with no history of chronic systemic diseases.

You may not qualify if:

  • Medically compromised patient.
  • Teeth with vertical fractures.
  • Non-restorable teeth.
  • Teeth when bleeding could not be induced.
  • Unable to attend follow-up visits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Kasprisin DO, Heiss R, Rausen AR. Cholelithiasis during remission of acute lymphocytic leukemia in a child. Clin Pediatr (Phila). 1981 Oct;20(10):678. No abstract available.

    PMID: 6944166BACKGROUND
  • Ruskin KJ, Tissot M. A new method of communication between anesthesiologists. Anesthesiology. 1993 Oct;79(4):867. doi: 10.1097/00000542-199310000-00037. No abstract available.

    PMID: 8214771BACKGROUND

MeSH Terms

Interventions

Blood Coagulation

Intervention Hierarchy (Ancestors)

HemostasisBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD researcher in pediatric dentistry and public health department

Study Record Dates

First Submitted

August 7, 2023

First Posted

August 25, 2023

Study Start

June 1, 2024

Primary Completion

December 1, 2024

Study Completion

October 1, 2025

Last Updated

February 6, 2024

Record last verified: 2023-09